The ERA-NET PRIOMEDCHILD (Priority Medicines For Children) is a partnership between research funding organizations from Estonia, Finland (accession in progress), France, Italy, Latvia (accession in progress), the Netherlands, Poland, Spain, United Kingdom and Sweden to bring coherence and cooperation to national research programmes and policies on research on Priority Medicines for Children. Germany participates in PRIOMEDCHILD as an associate Partner.

PRIOMEDCHILD will bring together European national programmes, policy makers and programme managers in the field of public medical research aiming at innovative research programmes and the utilization of research results on Priority Medicines for Children. Over 50% of the medicines used in children may not have been studied in this age group.

For the paediatric population (0-18 years) this means that medicines are used without proper information on dosage, potential toxicity and evidence of clincial safety and efficacy at the recommended dosages.
PRIOMEDCHILD aims to contribute to more effective and safer medicines for children.